David Inwards
Overview
Explore the profile of David Inwards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chohan K, Paludo J, Vallumsetla N, Larson D, King R, He R, et al.
Am J Hematol
. 2023 Jan;
98(3):432-439.
PMID: 36588384
Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, that predominately affects the elderly. We report the outcomes of young WM patients, evaluated over five decades, compared to their older counterparts,...
2.
McLaughlin N, Wang Y, Witzig T, Villasboas J, Habermann T, Inwards D, et al.
Leuk Lymphoma
. 2022 Nov;
64(2):371-377.
PMID: 36416595
Involvement of the central nervous system (CNS) is a rare complication of mantle cell lymphoma (MCL) with limited treatment options. We report the outcomes of 36 patients with CNS involvement...
3.
Kuhlman J, Alhaj Moustafa M, Jiang L, Iqbal M, Seegobin K, Wolcott Z, et al.
Clin Lymphoma Myeloma Leuk
. 2022 May;
22(8):e815-e825.
PMID: 35534379
Introduction: Leukemic involvement in high grade B cell lymphoma (L-HGBL) is rare and has been sparsely described in the literature. We report our experience in a large single institution multicenter...
4.
Iqbal M, Gil Castano Y, Paludo J, Rosenthal A, Li Z, Beltran M, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Oct;
22(2):e89-e95.
PMID: 34593359
Germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) at diagnosis is associated with superior long-term outcomes compared to non-GCB-DLBCL in patients treated with conventional chemo-immunotherapy. Whether cell of origin...
5.
Shah N, Ahn K, Litovich C, Sureda A, Kharfan-Dabaja M, Awan F, et al.
Blood Cancer J
. 2021 Apr;
11(4):82.
PMID: 33927193
No abstract available.
6.
Abeykoon J, Zanwar S, Ansell S, Muchtar E, He R, Greipp P, et al.
Am J Hematol
. 2021 Apr;
96(8):945-953.
PMID: 33909933
Comparative data guiding initial therapy for Waldenström macroglobulinemia (WM), an infrequently encountered non-Hodgkin lymphoma, are sparse. We evaluated three commonly used rituximab-based frontline regimens: rituximab-bendamustine (R-Benda); dexamethasone, rituximab, cyclophosphamide (DRC);...
7.
Ghosh N, Ahmed S, Ahn K, Khanal M, Litovich C, Aljurf M, et al.
JAMA Oncol
. 2020 Jun;
6(7):1011-1018.
PMID: 32496525
Importance: Reduced-intensity conditioning and nonmyeloablative conditioning (RIC-NMAC) regimens are frequently used in allogeneic hematopoietic cell transplant (HCT) for non-Hodgkin lymphoma. However, the optimal RIC-NMAC regimen in allogeneic HCT for non-Hodgkin...
8.
Jagadeesh D, Majhail N, He Y, Ahn K, Litovich C, Ahmed S, et al.
Cancer
. 2020 Feb;
126(10):2279-2287.
PMID: 32049359
Background: Although rituximab-based high-dose therapy is frequently used in diffuse large B cell lymphoma (DLBCL) patients undergoing autologous hematopoietic cell transplantation (auto-HCT), data supporting the benefits are not available. Herein,...
9.
Zanwar S, Abeykoon J, Durot E, King R, Perez Burbano G, Kumar S, et al.
Am J Hematol
. 2019 Dec;
95(3):274-281.
PMID: 31814157
Histological transformation in Waldenström macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88 mutation on transformation. We examined risk factors and outcomes associated with...
10.
Shah N, Ahn K, Litovich C, Sureda A, Kharfan-Dabaja M, Awan F, et al.
Blood Cancer J
. 2019 Dec;
9(12):97.
PMID: 31796726
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for relapsed/refractory and high-risk non-Hodgkin lymphoma (NHL). However, no large studies have evaluated allo-HCT utilization in elderly NHL patients (≥65 years)....